An observational study in Chronic Kidney Disease, sponsored by Boehringer Ingelheim. Active, not recruiting at 1 site in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-16.
Sponsored by Boehringer Ingelheim · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Renal Insufficiency, Chronic by Boehringer Ingelheim — none open to participants now, 4 under way, 2 of them phase 3. Renal Insufficiency, Chronic · Boehringer Ingelheim.
Among the 13 studies in Renal Insufficiency, Chronic by Boehringer Ingelheim, this one is one of 3 that started in 2025, is one of 3 observational ones, and was the 12th registered.
3,097 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →None of the 13 studies in Renal Insufficiency, Chronic by Boehringer Ingelheim is open now. The open studies under Renal Insufficiency, Chronic, anywhere →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15,000 is above the median of 213 across 835 observational studies indexed under Renal Insufficiency, Chronic.
Median enrollment 242 across the 10 interventional studies, 1,024 across the 3 observational. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 61 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
4 of the studies in Renal Insufficiency, Chronic by Boehringer Ingelheim that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06531824Phase 3Boehringer IngelheimEASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | 2026-12-31 |
| NCT07107945Phase 3Boehringer IngelheimA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | 2027-04-16 |
| NCT07063316Boehringer IngelheimSGLT2 Inhibitors and Renal Anemia in Japan: RWD | 2026-12-25 |
| NCT06527846Boehringer IngelheimPost Marketing Surveillance of JARDIANCE in Chronic Kidney Disease | 2027-03-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 13 studies in Renal Insufficiency, Chronic by Boehringer Ingelheim, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objectives of the study are:
A) Prescription patterns and treatment regimens for anemia, including analysis of medication types, dosing strategies, and duration of treatments B) Anemia-related healthcare costs C) Change in laboratory values
Chronic kidney disease patients registered in the Medical Data Vision (MDV) database in Japan.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Have evidence of anemia at the study cohort entry date or within 183 days before the study cohort entry date.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SGLT2 inhibitor
SGLT2 inhibitor
First occurrence of anemia (composite anemia outcomes)
The composite of anemia outcomes is defined as any of the following: * Hb \< 13.0 g/dL for men or \< 12.0 g/dL for women * Clinical diagnosis of anemia using ICD-10 diagnosis codes * Initiation of anemia treatment (Erythropoiesis-Stimulating Agents (ESAs), Hypoxia-Inducible Factor-Prolyl Hydroxylase (HIF-PH) inhibitors, iron preparations, or red blood cell (RBC) transfusion
Time frame: From the study cohort entry date to first event occurrence (for cases) or matched reference date (for controls), up to 13 years
Number of administered doses of ESA, HIF-PH inhibitors, iron preparations, and RBC transfusions
Erythropoiesis-Stimulating Agents (ESAs) Hypoxia-Inducible Factor-Prolyl Hydroxylase (HIF-PH) Red blood cell (RBC) transfusions -outcome evaluated as within-subject changes between pre- and post-index/reference periods
Time frame: 1, 3, and 6 months after cohort entry and after the index date (cases) or matched reference date (controls)
Anemia-related healthcare costs
Anemia-related medical costs are defined as the sum of direct medical costs associated with the treatment of anemia. These costs will include medication costs and costs related to RBC transfusion. -outcome evaluated as within-subject changes between pre- and post-index/reference periods
Time frame: 1, 3, and 6 months after cohort entry and after the index date (cases) or matched reference date (controls)
Frequency of administration of ESA, HIF-PH inhibitors, iron preparations, and RBC transfusions
-outcome evaluated as within-subject changes between pre- and post-index/reference periods
Time frame: 1, 3, and 6 months after cohort entry and after the index date (cases) or matched reference date (controls)
Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency
Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →